Multiple Myeloma (MM) Unknown Status Phase 2 Trials for DB01041 (Thalidomide)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

IndicationStatusPhase
DBCOND0040908 (Multiple Myeloma (MM))Unknown Status2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00124813Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple MyelomaTreatment
NCT00319865PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple MyelomaTreatment
NCT00349115TCD Followed by autoSCT for Newly Diagnosed MM PatientsTreatment
NCT01114048Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)Treatment